Thursday, March 13, 2008

Presentations from FDA ODAC Meeting Held March 13, 2008

On Thursday, March 13, 2008, Amgen presented the benefits and risks of Erythropoiesis-stimulating Agents (ESAs) in cancer patients with anemia due to concomitantly administered chemotherapy at a meeting with the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC).

Below are links to the slide presentations that Amgen and the FDA presented at the ODAC meeting. A link to the FDA Dockets Management page including the FDA briefing material is also provided.

Posted in